Cargando…

First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 patients

Primary central nervous system non-Hodgkin lymphomas (PCNS-NHLs) are extranodal B-cell lymphomas with poor prognosis. The role of high-dose therapy (HDT) followed by autologous blood stem cell transplantation (ASCT) as first-line therapy is still not clear. We retrospectively collected long-term fol...

Descripción completa

Detalles Bibliográficos
Autores principales: Brezina, T., von Dewitz, H., Schroeder, T., Ullrich, S., Nachtkamp, K., Reifenberger, G., Malzkorn, B., Sabel, M., Haas, R., Kobbe, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810459/
https://www.ncbi.nlm.nih.gov/pubmed/34982196
http://dx.doi.org/10.1007/s00277-021-04745-z
_version_ 1784644257733148672
author Brezina, T.
von Dewitz, H.
Schroeder, T.
Ullrich, S.
Nachtkamp, K.
Reifenberger, G.
Malzkorn, B.
Sabel, M.
Haas, R.
Kobbe, G.
author_facet Brezina, T.
von Dewitz, H.
Schroeder, T.
Ullrich, S.
Nachtkamp, K.
Reifenberger, G.
Malzkorn, B.
Sabel, M.
Haas, R.
Kobbe, G.
author_sort Brezina, T.
collection PubMed
description Primary central nervous system non-Hodgkin lymphomas (PCNS-NHLs) are extranodal B-cell lymphomas with poor prognosis. The role of high-dose therapy (HDT) followed by autologous blood stem cell transplantation (ASCT) as first-line therapy is still not clear. We retrospectively collected long-term follow up data of 61 consecutive patients with PCNS-NHL at the University Hospital Düsseldorf from January 2004 to December 2016. Thirty-six patients were treated with conventional chemoimmunotherapy (cCIT) only (CT-group). Seventeen patients received an induction cCIT followed by HDT and ASCT. In the CT-group, the overall response rate (ORR) was 61% (CR 47%, PR 14%), and there were 8% treatment-related deaths (TRD). Progression-free survival (PFS) was 31.8 months, and overall survival (OS) was 57.3 months. In the HDT-group, the ORR was 88% (59% CR, 29% PR), and there were 6% TRD. Median PFS and OS were not reached at 5 years. The 5-year PFS and OS were 64.7%. After a median follow up of 71 months, 10 patients (59%) were still alive in CR/PR following HDT and ASCT, one patient was treated for progressive disease (PD), and 7 had died (41%, 6 PD, 1 TRD). All patients achieving CR prior to HDT achieved durable CR. In the CT-group, 8 patients (22%) were alive in CR/PR after a median follow-up of 100 months. Twenty-eight patients died (78%, 24 PD, 2 TRD, 2 deaths in remission). In the univariate analysis, the HDT-group patients had significantly better PFS (not reached vs 31.8 months, p = 0.004) and OS (not reached vs 57.3 months, p = 0.021). The multivariate analysis showed HDT was not predictive for survival. Treatment with HDT + ASCT is feasible and offers the chance for long-term survival with low treatment-related mortality in younger patients. In this analysis, ORR, PFS and OS were better with HDT than with conventional cCIT alone. This result was not confirmed in the multivariate analysis, and further studies need to be done to examine the role of HDT in PCNSL.
format Online
Article
Text
id pubmed-8810459
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-88104592022-02-10 First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 patients Brezina, T. von Dewitz, H. Schroeder, T. Ullrich, S. Nachtkamp, K. Reifenberger, G. Malzkorn, B. Sabel, M. Haas, R. Kobbe, G. Ann Hematol Original Article Primary central nervous system non-Hodgkin lymphomas (PCNS-NHLs) are extranodal B-cell lymphomas with poor prognosis. The role of high-dose therapy (HDT) followed by autologous blood stem cell transplantation (ASCT) as first-line therapy is still not clear. We retrospectively collected long-term follow up data of 61 consecutive patients with PCNS-NHL at the University Hospital Düsseldorf from January 2004 to December 2016. Thirty-six patients were treated with conventional chemoimmunotherapy (cCIT) only (CT-group). Seventeen patients received an induction cCIT followed by HDT and ASCT. In the CT-group, the overall response rate (ORR) was 61% (CR 47%, PR 14%), and there were 8% treatment-related deaths (TRD). Progression-free survival (PFS) was 31.8 months, and overall survival (OS) was 57.3 months. In the HDT-group, the ORR was 88% (59% CR, 29% PR), and there were 6% TRD. Median PFS and OS were not reached at 5 years. The 5-year PFS and OS were 64.7%. After a median follow up of 71 months, 10 patients (59%) were still alive in CR/PR following HDT and ASCT, one patient was treated for progressive disease (PD), and 7 had died (41%, 6 PD, 1 TRD). All patients achieving CR prior to HDT achieved durable CR. In the CT-group, 8 patients (22%) were alive in CR/PR after a median follow-up of 100 months. Twenty-eight patients died (78%, 24 PD, 2 TRD, 2 deaths in remission). In the univariate analysis, the HDT-group patients had significantly better PFS (not reached vs 31.8 months, p = 0.004) and OS (not reached vs 57.3 months, p = 0.021). The multivariate analysis showed HDT was not predictive for survival. Treatment with HDT + ASCT is feasible and offers the chance for long-term survival with low treatment-related mortality in younger patients. In this analysis, ORR, PFS and OS were better with HDT than with conventional cCIT alone. This result was not confirmed in the multivariate analysis, and further studies need to be done to examine the role of HDT in PCNSL. Springer Berlin Heidelberg 2022-01-04 2022 /pmc/articles/PMC8810459/ /pubmed/34982196 http://dx.doi.org/10.1007/s00277-021-04745-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Brezina, T.
von Dewitz, H.
Schroeder, T.
Ullrich, S.
Nachtkamp, K.
Reifenberger, G.
Malzkorn, B.
Sabel, M.
Haas, R.
Kobbe, G.
First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 patients
title First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 patients
title_full First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 patients
title_fullStr First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 patients
title_full_unstemmed First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 patients
title_short First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 patients
title_sort first-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-hodgkin lymphomas—a single-centre experience in 61 patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810459/
https://www.ncbi.nlm.nih.gov/pubmed/34982196
http://dx.doi.org/10.1007/s00277-021-04745-z
work_keys_str_mv AT brezinat firstlinehighdosetherapyandautologousbloodstemcelltransplantationinpatientswithprimarycentralnervoussystemnonhodgkinlymphomasasinglecentreexperiencein61patients
AT vondewitzh firstlinehighdosetherapyandautologousbloodstemcelltransplantationinpatientswithprimarycentralnervoussystemnonhodgkinlymphomasasinglecentreexperiencein61patients
AT schroedert firstlinehighdosetherapyandautologousbloodstemcelltransplantationinpatientswithprimarycentralnervoussystemnonhodgkinlymphomasasinglecentreexperiencein61patients
AT ullrichs firstlinehighdosetherapyandautologousbloodstemcelltransplantationinpatientswithprimarycentralnervoussystemnonhodgkinlymphomasasinglecentreexperiencein61patients
AT nachtkampk firstlinehighdosetherapyandautologousbloodstemcelltransplantationinpatientswithprimarycentralnervoussystemnonhodgkinlymphomasasinglecentreexperiencein61patients
AT reifenbergerg firstlinehighdosetherapyandautologousbloodstemcelltransplantationinpatientswithprimarycentralnervoussystemnonhodgkinlymphomasasinglecentreexperiencein61patients
AT malzkornb firstlinehighdosetherapyandautologousbloodstemcelltransplantationinpatientswithprimarycentralnervoussystemnonhodgkinlymphomasasinglecentreexperiencein61patients
AT sabelm firstlinehighdosetherapyandautologousbloodstemcelltransplantationinpatientswithprimarycentralnervoussystemnonhodgkinlymphomasasinglecentreexperiencein61patients
AT haasr firstlinehighdosetherapyandautologousbloodstemcelltransplantationinpatientswithprimarycentralnervoussystemnonhodgkinlymphomasasinglecentreexperiencein61patients
AT kobbeg firstlinehighdosetherapyandautologousbloodstemcelltransplantationinpatientswithprimarycentralnervoussystemnonhodgkinlymphomasasinglecentreexperiencein61patients